Existence of FGFR1-5-HT1AR heteroreceptor complexes in hippocampal astrocytes. Putative link to 5-HT and FGF2 modulation of hippocampal gamma oscillations

dc.centroFacultad de Medicinaes_ES
dc.contributor.authorNarváez-Peláez, Manuel
dc.contributor.authorAndrade-Talavera, Yunieski
dc.contributor.authorValladolid-Acebes, Ismael
dc.contributor.authorFredriksson, Magnus
dc.contributor.authorSiegele, Pia
dc.contributor.authorHernandez-Sosa, Alejandro
dc.contributor.authorFisahn, André
dc.contributor.authorFuxe, Kjell
dc.contributor.authorBorroto Escuela, Dasiel Óscar
dc.date.accessioned2025-01-24T12:40:50Z
dc.date.available2025-01-24T12:40:50Z
dc.date.issued2020-06-15
dc.departamentoFisiología Humana, Histología Humana, Anatomía Patológica y Educación Físico Deportiva
dc.descriptionhttps://openpolicyfinder.jisc.ac.uk/id/publication/4662es_ES
dc.description.abstractThe majority of the fibroblast growth factor receptor 1-serotonin 1 A receptor (FGFR1-5-HT1AR) heterocomplexes in the hippocampus appeared to be located mainly in the neuronal networks and a relevant target for antidepressant drugs. Through a neurochemical and electrophysiological analysis it was therefore tested in the current study if astrocytic FGFR1-5-HT1AR heterocomplexes also exist in hippocampus. They may modulate the structure and function of astroglia in the hippocampus leading to possible changes in the gamma oscillations. Localization of hippocampal FGFR1-5-HT1AR heterocomplexes in astrocytes was found using in situ proximity ligation assay combined with immunohistochemistry using glial fibrillary acidic protein (GFAP) immunoreactivity as a marker for astroglia. Acute i.c.v. treatment with 8-OH-DPAT alone or together with basic fibroblast growth factor (FGF2) significantly increased FGFR1-5-HT1AR heterocomplexes in the GFAP positive cells, especially in the polymorphic layer of the dentate gyrus (PoDG) but also in the CA3 area upon combined treatment. No other hippocampal regions were studied. Also, structural plasticity changes were observed in the astrocytes, especially in the PoDG region, upon these pharmacological treatments. They may also be of relevance for enhancing the astroglial volume transmission with increased modulation of the neuronal networks in the regions studied. The effects of combined FGF2 and 5-HT agonist treatments on gamma oscillations point to a significant antagonistic interaction in astroglial FGFR1-5-HT1AR heterocomplexes that may contribute to counteraction of the 5-HT1AR-mediated decrease of gamma oscillations.es_ES
dc.description.sponsorshipThe work was supported by the Swedish Medical Research Council, Sweden (62X-00715-50-3) to KF, by Parkinson Fonden, Sweden to KF, and by Hjärnfonden, Sweden (F02018-0286), Hjärnfonden, Sweden (F02019-0296) and Karolinska Institutet Forskningsstiftelser, Sweden to D.O.B-E. D.O.B-E belongs to the “Academia de Biólogos Cubanos” group, Cuba. This work was also supported by the Proyecto Puente, Spain and the UMA18-FEDERJA-100, Spain to MN.es_ES
dc.identifier.doi10.1016/j.neuropharm.2020.108070
dc.identifier.urihttps://hdl.handle.net/10630/36936
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAttribution-NoDerivatives 4.0 Internacional*
dc.rights.accessRightsopen accesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nd/4.0/*
dc.subjectReceptores de neurotransmisoreses_ES
dc.subjectDepresión mentales_ES
dc.subjectSerotoninaes_ES
dc.subject.otherDepressiones_ES
dc.subject.otherSerotonines_ES
dc.subject.otherReceptor tyrosine kinasees_ES
dc.subject.otherReceptor-receptor interactions.es_ES
dc.titleExistence of FGFR1-5-HT1AR heteroreceptor complexes in hippocampal astrocytes. Putative link to 5-HT and FGF2 modulation of hippocampal gamma oscillationses_ES
dc.typejournal articlees_ES
dc.type.hasVersionSMURes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationf7a7d8e7-ceb6-4987-a532-927cdd751800
relation.isAuthorOfPublication.latestForDiscoveryf7a7d8e7-ceb6-4987-a532-927cdd751800

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Manuscript Narvaez et al. Neuropharmacology 2019.pdf
Size:
313.25 KB
Format:
Adobe Portable Document Format
Description:

Collections